)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
OncoZenge
OncoZenge (ONCOZ) investor relations material
OncoZenge Investing in Life Science 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investing in Life Science 2026 summary22 Sep, 2026
Market need and patient impact
Oral mucositis affects over one-third of cancer patients in Europe, causing severe pain and impacting quality of life.
Standard treatments like lidocaine, mouthwashes, and opioids often fail to provide sufficient relief.
Patients experience significant weight loss, risk of opioid dependence, and increased healthcare costs due to complications.
Product innovation and clinical progress
Developed BupiZenge, a dissolving lozenge using bupivacaine, offering localized pain relief for oral mucositis.
Phase III clinical trial is underway, with eight hospitals in Europe actively recruiting by end of September.
Clinical trial application approved in May, first patient recruited in July, aiming for clinical study report early next year.
Commercial and partnership strategy
Chose a partner-based commercial strategy, avoiding building own sales force for a single product.
Signed European distribution partnership with Molteni, a specialist in pain and addiction, covering over 40 countries.
Active discussions with pharma companies globally, with Asia-Pacific seen as the next likely region for partnership.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from OncoZenge
- European Phase III approval and milestone payments drive funding efforts amid rising R&D costs.ONCOZ
Q2 2026 - BupiZenge targets a 2028 European launch as a new standard for oral mucositis pain relief.ONCOZLife Science Conference 2026
- Phase III trial for BupiZenge™ nears EMA approval as liquidity is bolstered by new investments.ONCOZQ1 2026
- Advanced Phase III CTA submission, secured financing, and strengthened partnerships for BupiZenge™.ONCOZQ4 2025
- Fully funded for Phase III trial, advancing toward EU approval with strong partnerships.ONCOZQ3 2025
- Phase 3 trial for BupiZenge™ is funded and set for 2026, targeting EU approval in 2027.ONCOZQ2 2025
- BupiZenge™ phase 3 preparations advance as OncoZenge secures key partnership and financing.ONCOZQ3 2024
- Losses narrowed as OncoZenge prepares BupiZenge for Phase III and seeks a strategic partner.ONCOZQ2 2024
- Q1 2025 saw OncoZenge secure milestone revenue and key funding for its pivotal phase III trial.ONCOZQ1 2025
Next OncoZenge earnings date
Q3 202611 Nov, 2026
OncoZenge
Next OncoZenge earnings date
Q3 202611 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. Its products include Palonosetron Fertiginject, an antiemetic product developed and launched in the Nordics; and Yserenate, a pharmaceutical preparation that is used for the treatment of hyperammonemia in patients with N-acetylglutamate synthase deficiency, as well as for the treatment of hypophosphatemia in patients with chronic kidney disease. The company was founded in 2020 and is headquartered in Bromma, Sweden.